Search research articles
Contact Us
Filters
Showing results (291-300 of 357) with videos related to
Page
of 36
Sort By:
Plos Neglected Tropical Diseases
|
March 4, 2014
Comparative analysis of salivary gland transcriptomes of Phlebotomus orientalis sand flies from endemic and non-endemic foci of visceral leishmaniasis
Michaela Vlkova, Michal Sima, Iva Rohousova, et al.
Scientific Reports
|
September 7, 2016
Circulating Biomarkers of Immune Activation, Oxidative Stress and Inflammation Characterize Severe Canine Visceral Leishmaniasis
Manuela S Solcà, Bruno B Andrade, Melissa Moura Costa Abbehusen, et al.
Plos Neglected Tropical Diseases
|
March 31, 2010
Using recombinant proteins from Lutzomyia longipalpis saliva to estimate human vector exposure in visceral Leishmaniasis endemic areas
Ana Paula Souza, Bruno Bezerril Andrade, Dorlene Aquino, et al.
Blood
|
March 22, 2023
A bispecific inhibitor of complement and coagulation blocks activation in complementopathy models via a novel mechanism
John F Andersen, Haotian Lei, Ethan C Strayer, et al.
Vaccines
|
October 28, 2025
AGS-v PLUS, a Mosquito Salivary Peptide Vaccine, Modulates the Response to <i>Aedes</i> Mosquito Bites in Humans
Liam Barningham, Ian M Carr, Siân Jossi, et al.
Biorxiv : the Preprint Server for Biology
|
April 8, 2025
Human sand fly challenge elicits saliva-specific innate and T<sub>H</sub>1-polarized immunity that promotes <i>Leishmania</i> killing
Maha Abdeladhim, Clarissa Teixeira, Roseanne Ressner, et al.
Communications Biology
|
May 5, 2026
Human sand fly challenge elicits saliva-specific innate and type 1-polarized immunity that promotes Leishmania killing
Maha Abdeladhim, Clarissa Teixeira, Roseanne Ressner, et al.
Ebiomedicine
|
November 27, 2022
Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial
DeAnna J Friedman-Klabanoff, Megan Birkhold, Mara T Short, et al.
Plos Neglected Tropical Diseases
|
November 28, 2017
Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis
Pedro Cecílio, Begoña Pérez-Cabezas, Laura Fernández, et al.
Ticks and Tick-Borne Diseases
|
July 10, 2025
IxsS7: A novel biomarker for Ixodes scapularis tick bite exposure in humans
Patrick H Kelly, Derek A T Cummings, Eva Iniguez, et al.
Page
of 36
Search research articles
Search
Showing results (291-300 of 357) with videos related to
Sort By:
Page
of 36
Plos Neglected Tropical Diseases
|
March 4, 2014
Comparative analysis of salivary gland transcriptomes of Phlebotomus orientalis sand flies from endemic and non-endemic foci of visceral leishmaniasis
Michaela Vlkova, Michal Sima, Iva Rohousova, et al.
Scientific Reports
|
September 7, 2016
Circulating Biomarkers of Immune Activation, Oxidative Stress and Inflammation Characterize Severe Canine Visceral Leishmaniasis
Manuela S Solcà, Bruno B Andrade, Melissa Moura Costa Abbehusen, et al.
Plos Neglected Tropical Diseases
|
March 31, 2010
Using recombinant proteins from Lutzomyia longipalpis saliva to estimate human vector exposure in visceral Leishmaniasis endemic areas
Ana Paula Souza, Bruno Bezerril Andrade, Dorlene Aquino, et al.
Blood
|
March 22, 2023
A bispecific inhibitor of complement and coagulation blocks activation in complementopathy models via a novel mechanism
John F Andersen, Haotian Lei, Ethan C Strayer, et al.
Vaccines
|
October 28, 2025
AGS-v PLUS, a Mosquito Salivary Peptide Vaccine, Modulates the Response to <i>Aedes</i> Mosquito Bites in Humans
Liam Barningham, Ian M Carr, Siân Jossi, et al.
Biorxiv : the Preprint Server for Biology
|
April 8, 2025
Human sand fly challenge elicits saliva-specific innate and T<sub>H</sub>1-polarized immunity that promotes <i>Leishmania</i> killing
Maha Abdeladhim, Clarissa Teixeira, Roseanne Ressner, et al.
Communications Biology
|
May 5, 2026
Human sand fly challenge elicits saliva-specific innate and type 1-polarized immunity that promotes Leishmania killing
Maha Abdeladhim, Clarissa Teixeira, Roseanne Ressner, et al.
Ebiomedicine
|
November 27, 2022
Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial
DeAnna J Friedman-Klabanoff, Megan Birkhold, Mara T Short, et al.
Plos Neglected Tropical Diseases
|
November 28, 2017
Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis
Pedro Cecílio, Begoña Pérez-Cabezas, Laura Fernández, et al.
Ticks and Tick-Borne Diseases
|
July 10, 2025
IxsS7: A novel biomarker for Ixodes scapularis tick bite exposure in humans
Patrick H Kelly, Derek A T Cummings, Eva Iniguez, et al.
Page
of 36